Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes existing data on the efficacy and safety of topical minoxidil for androgenetic alopecia but reports no new clinical findings; the authors emphasize the need for realistic evaluation of its potential.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

This study observed that DMSO-modified liposomes enhanced the topical delivery of finasteride, improving hair follicle density and growth phase ratio in a rat model of testosterone-induced alopecia.

This review examined existing studies on topical finasteride for androgenetic alopecia and noted inconsistent application of hair evaluation methods, suggesting a need for standardization in future research.

This article discusses the FDA-approved treatments for male pattern baldness, minoxidil and finasteride, but does not report new findings about their efficacy.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.

This study suggests that novel lipid nanoparticle formulations may be suitable for delivering anti-alopecia compounds like minoxidil and finasteride, although their skin penetration was limited.

This study found that the U.S. stock market responded heterogeneously to the latest presidential elections, with positive reactions in the Energy, Financials, and Industrials sectors but poorer performance among firms with better environmental scores.

This study developed lipid nanoparticles for delivering minoxidil and finasteride to the dermis and hair follicles, showing stability and a desired prolonged release, though with low skin penetration levels.

This study found that while there were no significant objective changes in facial hirsutism using topical finasteride, most patients perceived a reduction in hair growth after treatment.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

Topical minoxidil successfully treated temporal triangular alopecia.

This corrigendum clarifies that withdrawal rates due to treatment-related side effects were misstated in a study on topical finasteride for male androgenetic alopecia; higher withdrawal rates were associated with oral finasteride, not topical.

The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.

This correspondence critiques a previous report advocating finasteride for frontal fibrosing alopecia, arguing that the evidence on its safety and effectiveness is inconclusive, particularly due to methodological limitations.

This study found that the combination of platelet-rich plasma with topical minoxidil and finasteride was more effective in treating androgenetic alopecia than the conventional minoxidil and finasteride therapy alone.

In this study, the combination of finasteride and minoxidil significantly increased hair growth in balding male stumptail macaques compared to each drug alone.

Topical finasteride doesn't reduce DHT levels, hinting at an endocrine role in hair loss.

Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.

This study found that minoxidil applied to a damp scalp may increase drug penetration in vitro, potentially improving treatment effectiveness.

In AGA animal models, this study found that finasteride-loaded microspheres provided rapid and sustained dihydrotestosterone suppression, promoting hair regrowth through dual-phase drug release.

This study reported that both topical methotrexate 1% gel and minoxidil 5% gel were effective in treating localized alopecia areata, with no significant differences in efficacy between the two treatments.

This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.

In this self-controlled comparative study of 16 women with Female Pattern Hair Loss, MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced cases compared to standard Minoxidil treatment, though overall effectiveness was similar.

This study found that liquid crystalline nanoparticles formulated with Cremophor surfactants significantly enhanced skin permeation of finasteride compared to lower surfactant concentrations.

In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.

This study found that topical finasteride was absorbed into the bloodstream to a minimal extent in male rats, even with repeated applications, suggesting low systemic exposure.

This study found that in an androgenetic alopecia mouse model, phospholipid-bile salt mixed micelles for topical Finasteride delivery improved hair regrowth and reduced systemic absorption compared to a hydroalcoholic solution, suggesting a safer and more effective treatment option.

This review, authored by Deirdre A. Buckley, explores key concepts in managing dermatological conditions through topical therapies, including formulation considerations, prescribing practices, and potential hazards associated with their use.